{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:19:37Z","timestamp":1759666777608,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:00:00Z","timestamp":1572048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Canc Educ"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>The purpose of the study is to describe oncologists\u2019 perceptions and opinions about patient eligibility, guidelines, and barriers for use of granulocyte colony-stimulating factor (G-CSF), overall and stratified by their affiliation with the Oncology Care Model (OCM). In May 2018, we invited and recruited practicing US oncologists from a national database for an online survey. Level of agreement was identified using a seven-point scale, ranging from strongly disagree to strongly agree. Of 200 participating oncologists, 70 were OCM-affiliated. Overall, 65% of oncologists agreed or strongly agreed that all patients at high risk of febrile neutropenia (FN) should receive prophylactic G-CSF, and half agreed or strongly agreed that benefits of G-CSF outweigh the potential adverse effects. The most common barriers to G-CSF use for patients at high risk of FN included patient refusal (37.1% of OCM-affiliated oncologists vs. 21.5% of non-OCM-affiliated oncologists), not on protocol\/not supported by guidelines (32.9% vs. 23.1%), lack of reimbursement to practice (30.0% vs. 15.4%), and concerns about insurance coverage (22.9% vs. 26.9%). More OCM-affiliated oncologists reported that their practices offer and strongly encourage adherence to a specific protocol for G-CSF use (49.2%) versus non-OCM oncologists (31.3%). Despite recommendations from national guidelines and strong evidence from randomized, controlled clinical trials, only two thirds of oncologists agree or strongly agree that all patients at high risk of FN should receive primary G-CSF prophylaxis. Decisions about G-CSF prophylaxis may be affected by factors other than risk of FN, such as patient choice, practice protocols\/guidelines, lack of reimbursement, and insurance coverage.<\/jats:p>","DOI":"10.1007\/s13187-019-01638-8","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T14:04:32Z","timestamp":1572098672000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Survey of Oncologists\u2019 Perceptions and Opinions Regarding the Use of Granulocyte Colony-Stimulating Factors"],"prefix":"10.1007","volume":"35","author":[{"given":"Alicia","family":"Hawkins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alysa","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-5349","authenticated-orcid":false,"given":"Prasad L.","family":"Gawade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Belani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Kelsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,26]]},"reference":[{"issue":"10","key":"1638_CR1","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. \nhttps:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"5","key":"1638_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3892\/etm.2011.312","volume":"2","author":"MB Schilling","year":"2011","unstructured":"Schilling MB, Parks C, Deeter RG (2011) Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2(5):859\u2013866. \nhttps:\/\/doi.org\/10.3892\/etm.2011.312","journal-title":"Exp Ther Med"},{"issue":"23","key":"1638_CR3","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116(23):5555\u20135563. \nhttps:\/\/doi.org\/10.1002\/cncr.25332","journal-title":"Cancer"},{"issue":"3","key":"1638_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1638_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917\u20131927. \nhttps:\/\/doi.org\/10.1002\/cncr.25691","journal-title":"Cancer"},{"key":"1638_CR6","doi-asserted-by":"publisher","first-page":"CD003039","DOI":"10.1002\/14651858.CD003039.pub2","volume":"10","author":"R Mhaskar","year":"2014","unstructured":"Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B (2014) Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 10:CD003039. \nhttps:\/\/doi.org\/10.1002\/14651858.CD003039.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"1638_CR7","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167. \nhttps:\/\/doi.org\/10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"issue":"6","key":"1638_CR8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184. \nhttps:\/\/doi.org\/10.1200\/JCO.2005.09.102","journal-title":"J Clin Oncol"},{"issue":"3","key":"1638_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164\u2013170. \nhttps:\/\/doi.org\/10.1056\/NEJM199107183250305","journal-title":"N Engl J Med"},{"key":"1638_CR10","unstructured":"Crawford J, Becker PS, Alwan L, et al 2018 NCCN clinical practice guidelines in oncology: myeloid growth factors. Version 2. \nwww.nccn.org\n\n. August 3, 2018. Accessed December 6, 2018"},{"issue":"4","key":"1638_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427\u2013431. \nhttps:\/\/doi.org\/10.1093\/cid\/ciq147","journal-title":"Clin Infect Dis"},{"issue":"28","key":"1638_CR12","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"8","key":"1638_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/ajh.24412","volume":"91","author":"LK Hicks","year":"2016","unstructured":"Hicks LK, Rajasekhar A, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O\u2019Brien SH, Panepinto JA, Pasquini MC, Sarode R, Wood WA (2016) Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology. Am J Hematol 91(8):787\u2013792. \nhttps:\/\/doi.org\/10.1002\/ajh.24412","journal-title":"Am J Hematol"},{"issue":"12","key":"1638_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/jnci\/djr152","volume":"103","author":"AL Potosky","year":"2011","unstructured":"Potosky AL, Malin JL, Kim B, Chrischilles EA, Makgoeng SB, Howlader N, Weeks JC (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103(12):979\u2013982. \nhttps:\/\/doi.org\/10.1093\/jnci\/djr152","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"1638_CR15","first-page":"678","volume":"16","author":"SD Ramsey","year":"2010","unstructured":"Ramsey SD, McCune JS, Blough DK, McDermott CL, Clarke L, Malin JL, Sullivan SD (2010) Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer. Am J Manag Care 16(9):678\u2013686","journal-title":"Am J Manag Care"},{"issue":"10","key":"1638_CR16","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00520-017-3720-x","volume":"25","author":"R Sosa","year":"2017","unstructured":"Sosa R, Li S, Molony JT, Liu J, Stryker S, Collins AJ (2017) Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer 25(10):3123\u20133132. \nhttps:\/\/doi.org\/10.1007\/s00520-017-3720-x","journal-title":"Support Care Cancer"},{"issue":"5","key":"1638_CR17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","volume":"24","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2016) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Cancer 24(5):2309\u20132316. \nhttps:\/\/doi.org\/10.1007\/s00520-015-3036-7","journal-title":"Support Care Cancer"},{"key":"1638_CR18","unstructured":"Neulasta [package insert] Thousand Oaks: Amgen Inc., June 2018"},{"issue":"1","key":"1638_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00520-017-3841-2","volume":"26","author":"A Brett Hauber","year":"2018","unstructured":"Brett Hauber A, Mange B, Price MA, Wolin D, Bensink M, Kaye JA, Chandler D (2018) Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. Support Care Cancer 26(1):251\u2013260. \nhttps:\/\/doi.org\/10.1007\/s00520-017-3841-2","journal-title":"Support Care Cancer"},{"key":"1638_CR20","unstructured":"Centers for Medicare & Medicaid Services Oncology care model. \nhttps:\/\/innovation.cms.gov\/initiatives\/oncology-care\/\n\n. Updated October 31, 2018. Accessed December 6, 2018"},{"key":"1638_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.14694\/EDBK_174909","volume":"37","author":"R Kline","year":"2017","unstructured":"Kline R, Adelson K, Kirshner JJ, Strawbridge LM, Devita M, Sinanis N, Conway PH, Basch E (2017) The oncology care model: perspectives from the Centers for Medicare & Medicaid Services and participating oncology practices in academia and the community. Am Soc Clin Oncol Educ Book 37:460\u2013466. \nhttps:\/\/doi.org\/10.14694\/EDBK_174909","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1638_CR22","series-title":"Applied Social Research Methods Series","volume-title":"Survey Research Methods","author":"FJ Fowler","year":"2014","unstructured":"Fowler FJ (2014) Survey Research Methods, Applied Social Research Methods Series, 5th edn. SAGE Publications, Thousand Oaks","edition":"5"},{"issue":"6","key":"1638_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/cam4.344","volume":"3","author":"G Barnes","year":"2014","unstructured":"Barnes G, Pathak A, Schwartzberg L (2014) G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use. Cancer Med 3(6):1477\u20131484. \nhttps:\/\/doi.org\/10.1002\/cam4.344","journal-title":"Cancer Med"},{"issue":"9","key":"1638_CR24","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1007\/s00520-016-3193-3","volume":"24","author":"S Marion","year":"2016","unstructured":"Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D (2016) \u201cSame-day\u201d administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer 24(9):3889\u20133896. \nhttps:\/\/doi.org\/10.1007\/s00520-016-3193-3","journal-title":"Support Care Cancer"},{"key":"1638_CR25","unstructured":"Abt Associates First Annual Report from the Evaluation of the Oncology Care Model: Baseline Period. Prepared for the Centers for Medicare & Medicaid Services under contract HHSM-500-2014-00026I T0003. \nhttps:\/\/downloads.cms.gov\/files\/cmmi\/ocm-baselinereport.pdf\n\n. February 1, 2018. Accessed December 6, 2018"},{"issue":"11","key":"1638_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1023\/A:1008353130228","volume":"10","author":"CL Bennett","year":"1999","unstructured":"Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ (1999) The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann Oncol 10(11):1355\u20131359","journal-title":"Ann Oncol"},{"issue":"11","key":"1638_CR27","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1200\/JCO.1999.17.11.3676","volume":"17","author":"CL Bennett","year":"1999","unstructured":"Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 17(11):3676\u20133681. \nhttps:\/\/doi.org\/10.1200\/JCO.1999.17.11.3676","journal-title":"J Clin Oncol"},{"issue":"8","key":"1638_CR28","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2000.18.8.1764","volume":"18","author":"G Swanson","year":"2000","unstructured":"Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET (2000) Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system. J Clin Oncol 18(8):1764\u20131770. \nhttps:\/\/doi.org\/10.1200\/JCO.2000.18.8.1764","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Education"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-019-01638-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13187-019-01638-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13187-019-01638-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T23:42:04Z","timestamp":1603582924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13187-019-01638-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1638"],"URL":"https:\/\/doi.org\/10.1007\/s13187-019-01638-8","relation":{},"ISSN":["0885-8195","1543-0154"],"issn-type":[{"type":"print","value":"0885-8195"},{"type":"electronic","value":"1543-0154"}],"subject":[],"published":{"date-parts":[[2019,10,26]]},"assertion":[{"value":"26 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AH, AM, and MM are employed by Adelphi Research, which received payment from Amgen Inc. to conduct the research activities presented in this manuscript. PLG, RB, and MAK are employees of, and hold stock in, Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}